Friday, 25. 7. 2020          

Cancer Cell Research (Online ISSN: 2161-2609)


Current Issue

Vol.7 No.27


Article: Second generation sequencing was performed to detect the gene mutation of PIk3CA in gynecological tumors and its relationship with the prognosis of patients
by Yuanli Guo, Junfeng Liu,Chen Shan
Cancer Cell Research 2020 7(27) 714-719; published online  15 July 2020
Abstract: To investigate the gene mutation of PIk3CA in gynecological tumors and analyze the relationship between PIk3CA and median survival time. Our study included gynecologic tumor patients 110 cases ((40 cases of cervical cancer, 40 cases of endometrial carcinoma, 30 cases of ovarian cancer) from January 2011 1 to August 2019, the First Affiliated Hospital of Sun Yat-sen University and Sun Yat-sen University Affiliated Hospital of Department of Gynaecology. Paraffin tumor samples from patients with postoperative, cut out the white piece, extract DNA, using the second generation sequencing of high-throughput sequencing platform, access to genetic testing results, the Kaplan-Meier survival curve analysis state of PIk3CA gene and the relationship between gynecological malignant tumor patients' overall survival time. In 110 patients with gynecological tumor, 61 cases (55.45%) patients had PIk3CA gene mutations, consensus don't 9745 variants, including 7215 single nucleotide mutation and 2530 missing or insertion mutation, type of PIk3CA mutations in patients with cervical cancer and ovarian cancer gene amplification, highly PIk3CA mutations in endometrial carcinoma was 36.67% (11/30), cervical cancer was 57.5% (23/40), ovarian cancer was 67.5% (27/40), compared with tissue adjacent to carcinoma (P < 0.05). The follow-up period was June 1, 2019, and a total of 98 patients were followed up. In cervical cancer and ovarian cancer, the poor prognosis of patients with PIk3CA gene mutation was significantly reduced in the non-mutation group (P=0.001), but no correlation was found between PIk3CA gene mutation and the survival time of patients in endometrial cancer. PIk3CA gene is highly extended in gynecological tumors, especially in ovarian cancer and cervical cancer, and is closely related to the poor prognosis of patients, which is great value for guiding clinical prognosis and guiding precise treatment.

Open Access Download (free) PDF


Article: Research progress of hematological indicators related to the prognosis of Small-cell lung cancer that can be easily ignored in clinical work
by Haocheng Wang, Ya Dong, Dongfeng Shan, Xue Yang, Qi Qi, Linwei Zhang, Zhuang Yu
Cancer Cell Research 2020 7(27) 720-728; published online   25 August 2020
Abstract: Lung cancer has the highest incidence and mortality in the world. Small-cell lung cancer (SCLC) accounts for about 15% of the total lung cancer, which belongs to neuroendocrine tumor, and among the patients, there are about 1/3 belong to the Limited Stage (LS). Chemotherapy combined with radiotherapy is the standard treatment for patients with LS-SCLC patients. However, SCLC is extremely aggressive and prone to early distant metastasis, and most of the patients are already in the Extensive Stage (ES) when they start seeking treatment. The prognosis of ES-SCLC patients is very poor, and its treatment has made little progress in recent decades. Therefore, sensitive and accurate indicators are needed to evaluate the prognosis of patients before starting treatment. Many studies have used hematology indexes at the initial diagnosis to predict the prognosis of SCLC patients, it involves liver function, routine blood coagulation and routine blood tests, including lactate dehydrogenase, fibrinogen, D-dimer, the ratio of neutrophils to lymphocytes(NLR), the ratio of platelets to lymphocytes(PLR), etc., which can play a role in the clinical work to indicate the treatment node.

Open Access Download (free) PDF


Article: Research progress on the prevention of colorectal cancer with Phytic Acid
by Jingjing Wang, Genquan Jin, Xiubo Jiang
Cancer Cell Research 2020 7(27) 729-735; published online  25 August 2020
Abstract: Phytic acid is an inositol ester containing six molecules of phosphoric acid, which is ubiquitous in plant seeds. It has various biological effects such as chelating, anti-oxidation, regulating immunity, anti-tumor, reducing inflammation, and inducing autophagy. A large number of animal and in vitro experiments have confirmed that phytic acid is a broad-spectrum anti-tumor substance that has effects on different cell and tissue systems. The number of people diagnosed with colorectal cancer each year is second only to lung cancer and breast cancer, ranking third in the world. It is a common gastrointestinal malignant tumor in my country. Metastasis is a key feature of malignant tumors, and it is also a difficult point in the treatment of cancer. Most treatments for colorectal cancer have side effects, and phytic acid has no obvious toxicity to normal cells. It can inhibit the metastasis of colorectal cancer, but its specific mechanism is not clear. If the mechanism of action can be clarified, it will provide a new target for the prevention and treatment of colorectal cancer. In this article, we reviewed the research progress of phytic acid and the mechanism of action of colorectal cancer metastasis.

Open Access Download (free) PDF


Article: Advances in anticancer activity of natural products from fungi
by Chen Liu, Yajie Shao, Feilong Deng, Fang Yuan, Yuchen Chen, Shiyi Wen,
      Jingyuan Zhang, Wen Zhao, Zekun He, Jinyi Yan, Xiangyi Cui, Xinyue Sun,
       Changwu Yue, Yuhong Lv
Cancer Cell Research 2020 7(27) 736-743; published online 25 September 2020
Abstract: The species and structure of active natural products from fungi are rich and diverse, which can affect many physiological and biochemical processes and are an important source of clinical antitumor drugs. In this paper, the origin, activity and mechanism of antifungal natural products are reviewed, and their future applications are prospected.

Open Access Download (free) PDF


Article: Application of ixazomib monotherapy and combination therapy in patients with multiple myeloma
by Shimeng Wang, Ying Wu, Wang Wei
Cancer Cell Research 2020 7(27) 744-748; published online  25 September 2020
Abstract: In the past few decades, the survival rate of patients with multiple myeloma has improved significantly. This improvement is mainly due to the development of proteasome inhibitors and immunomodulatory drugs, which are the cornerstone of the treatment of multiple myeloma. Ixazomib is a selective and reversible proteasome inhibitor. It can be used as a single agent or combined with other immunomodulators to treat multiple myeloma. This article mainly reviews the effectiveness and safety evaluation of ixazomib monotherapy and its combination therapy in patients with multiple myeloma prospected.

Open Access Download (free) PDF


 

 
��ҳģ��